What may be the markers of the male equivalent of polycystic ovary syndrome?

被引:24
|
作者
Dusková, M [1 ]
Cermakova, I [1 ]
Hill, M [1 ]
Vanková, M [1 ]
Sámalíková, P [1 ]
Stárka, L [1 ]
机构
[1] Inst Endocrinol, Narodni 8, Prague 11694 1, Czech Republic
关键词
premature androgenic alopecia; polycystic ovary syndrome; SHBG; insulin tolerance; male phenotype of PCOS;
D O I
10.33549/physiolres.930573
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women (with a prevalence of 5-10 %), is characterized by hormonal and metabolic imbalance. Complexity of symptoms of close relatives of women with PCOS and genetic autosomal trait initiated a hypothesis about the existence of a male equivalent of PCOS. Premature alopecia was suggested as one of the signs of a male phenotype of this syndrome. The present study investigated a group of 30 men, in which premature hair loss started before 30 years of age. In all patients, their hormonal profile was determined. It was possible to form two subgroups. The first one showed similar hormonal changes as women with PCOS, the other had either no anomalies in steroid spectrum or just only lower level of sexual hormones binding globulin (SHBG). Both subgroups did not differ in either BMI or age. In all men with premature alopecia insulin tolerance test was also carried out and the occurrence of allele 3 INS VNTR was investigated, which is one of the candidate genes for PCOS. The subgroup with hormonal changes resembling those of women with PCOS showed a significantly higher insulin resistance than the group without these changes. About one third of the premature balding men showed the combination of hormonal shifts and higher insulin resistance. This frequency corresponds to the prevalence of PCOS in women. There was no significant difference between the two subgroups in the occurrence of allele 3 INS VNTR.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 50 条
  • [1] What Is the Male Polycystic Ovary Syndrome Phenotype?
    Welt, Corrine K.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (05): : E2188 - E2189
  • [2] Male polycystic ovary syndrome equivalent: A response to Di Guardo et al
    Cannarella, Rossella
    La Vignera, Sandro
    Barbagallo, Federica
    Condorelli, Rosita A.
    Calogero, Aldo E.
    [J]. MEDICAL HYPOTHESES, 2020, 137
  • [3] Polycystic ovary syndrome: Endometrial markers
    Piltonen, Terhi T.
    [J]. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2016, 37 : 66 - 79
  • [4] Anti-Mullerian Hormone and Polycystic Ovary Syndrome in Women and Its Male Equivalent
    di Clemente, Nathalie
    Racine, Chrystele
    Rey, Rodolfo A.
    [J]. BIOMEDICINES, 2022, 10 (10)
  • [5] What is adolescent polycystic ovary syndrome?
    Pena, Alexia S.
    Metz, Michael
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2018, 54 (04) : 351 - 355
  • [6] POLYCYSTIC-OVARY SYNDROME - WHAT IS IT
    VAITUKAITIS, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (20): : 1245 - 1246
  • [7] Treatment may be on the horizon for polycystic ovary syndrome
    Wunsch, H
    [J]. LANCET, 1999, 353 (9164): : 1594 - 1594
  • [8] Inflammatory Markers in Women with Polycystic Ovary Syndrome
    Rudnicka, E.
    Kunicki, M.
    Suchta, K.
    Machura, P.
    Grymowicz, M.
    Smolarczyk, R.
    [J]. BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [9] The importance of inflammation markers in polycystic ovary syndrome
    Ozay, Ali Cenk
    Ozay, Ozlen Emekci
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2021, 67 (03): : 411 - 417
  • [10] Inflammatory markers in women with polycystic ovary syndrome
    Ardawi, Mohamed S.
    Rouzi, Abdulrahim A.
    [J]. REPRODUCTIVE SCIENCES, 2008, 15 (02) : 167A - 167A